What's Happening?
Exelixis and Natera have announced a collaboration on the STELLAR-316 trial, a Phase 3 pivotal study evaluating zanzalintinib for patients with resected stage II/III colorectal cancer. The trial will use
Natera's Signatera assay to identify MRD-positive patients for enrollment and monitor response to therapy. The primary endpoint is disease-free survival, with the trial expected to begin in mid-2026. This collaboration aims to address the unmet needs of colorectal cancer patients who are MRD-positive and at high risk of recurrence.
Why It's Important?
Colorectal cancer is a major health concern in the U.S., being the third most common cancer and the second leading cause of cancer-related deaths. The STELLAR-316 trial represents a significant step in developing targeted therapies for high-risk patients, potentially improving outcomes and setting new standards in cancer treatment. The use of MRD-guided treatment could lead to more personalized and effective cancer care, influencing future clinical practices and research.
What's Next?
Exelixis plans to initiate the STELLAR-316 trial in mid-2026, with the potential to make zanzalintinib the first MRD-guided treatment for colorectal cancer. The trial's success could lead to regulatory approvals and broader applications of MRD-guided therapies in oncology. This collaboration may also pave the way for further partnerships and innovations in cancer treatment.
